Breast tissue-specific epigenetic clock (BTEC): age prediction and distorted age in tumor-adjacent and tumor samples
A breast tissue-specific epigenetic clock (BTEC), built from 553 healthy breast tissue samples, predicted chronological age better than existing clocks; in tumor-adjacent and tumor samples its age predictions deviated, most strongly in tumor samples. [1]
Automatic summary · not editorially reviewed
The key findings
BTEC was developed from DNA methylation data of 553 healthy breast tissue samples across seven studies and predicted chronological age with r = 0.91 and a mean absolute error of 3.0 years. [1]
In tumor samples, the average difference between BTEC-predicted and chronological age was -14 to -15 years, and the distortion was greater in HER2+ and TNBC than in HR+ tumors. [1]
In an exploratory analysis, extreme BTEC-derived epigenetic age acceleration was associated with survival in HR+ breast cancer patients. [1]
The source at a glance
- Study type / format
- Abstract of a study developing and testing a DNA methylation-based age prediction model
- Population / context
- Healthy breast tissue samples (553) and tumor-adjacent and tumor samples, including HR+, HER2+ and TNBC subtypes, described in the abstract.
- Summary based on
- Study abstract
- Original publication
- September 11, 2026
BTEC built from 553 healthy breast samples
The abstract reports that classical clocks such as Horvath's and Hannum's predicted chronological age poorly in breast tissue. The researchers therefore developed a Breast Tissue-specific Epigenetic Clock (BTEC) using DNA methylation data from 553 healthy breast tissue samples across seven studies. BTEC correlated with chronological age at r = 0.91 and had a mean absolute error of 3.0 years, without dataset-specific regression adjustments. It performed consistently across ancestry groups, whereas existing clocks showed variable ancestry-related biases.
Supporting source [1]
Deviations in tumor-adjacent and tumor samples
For tumor-adjacent samples, BTEC's chronological age predictions showed distortions, with an average deviation of -2.3 years. In tumor samples the average difference between predicted and chronological age was -14 to -15 years. By molecular subtype, the distortion was greater in the more aggressive HER2+ and TNBC tumors than in HR+ tumors. The authors conclude that breast tumors do not generally show accelerated epigenetic aging.
Supporting source [1]
Exploratory survival link in HR+ patients
The probes used by BTEC were associated with known oncogenes such as JAK1, TP73, PDGFRA, CCND1 and STAT5B and with cancer-related pathways including Wnt, Hedgehog and ErbB signaling. In an exploratory analysis, extreme deviations in epigenetic age, measured as BTEC-derived epigenetic age acceleration, were associated with patient survival in HR+ breast cancer patients. The abstract calls this a potential prognostic value; it does not establish that the clock causes outcomes or that it is ready for clinical use.
Supporting source [1]
How to interpret this
This explainer is based only on the abstract; the full text was not reviewed. The abstract does not report follow-up duration, how survival was analyzed, or the size of the survival analysis, and the survival finding is described as exploratory. Associations do not show causation, and the clock is a research measure, not a validated clinical tool.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Garma LD, Pernas S, Fullana B, Vethencourt A, Vicente Baz D, García Manrique T, García Campelo R, Reboredo C, Terrasa J, Perello A, Colomer R, Jiménez D, Vera García R, de la Cruz Sánchez S, Bermejo B, Tapia M, González Santiago S, Quintela-Fandino M. · europepmc.org · September 11, 2026